87001-32-9

Usage

Uses

Used in Pharmaceutical Synthesis:
4-(Benzyloxy)benzene-1-sulfonyl chloride is used as a reagent for the synthesis of pharmaceuticals. Its strong electrophilic nature allows for efficient reactions such as aromatic substitutions and additions to alkenes, facilitating the creation of complex organic molecules with potential medicinal applications.
Used in Agrochemical Production:
In the agrochemical industry, 4-(Benzyloxy)benzene-1-sulfonyl chloride is utilized as a reagent for the synthesis of various agrochemicals. Its ability to participate in key chemical reactions contributes to the development of compounds that can be used in crop protection and other agricultural applications.
Used in Organic Synthesis:
4-(Benzyloxy)benzene-1-sulfonyl chloride is employed as a reagent in organic synthesis for the preparation of a wide range of organic compounds. Its strong electrophilicity makes it suitable for various reaction types, including aromatic substitutions and alkene additions, enabling the synthesis of complex organic molecules for diverse applications.
Safety Considerations:
It is important to handle 4-(Benzyloxy)benzene-1-sulfonyl chloride with care, as it is corrosive and can cause irritation to the skin, eyes, and respiratory system. Proper safety measures, including the use of personal protective equipment and working in well-ventilated areas, should be taken to minimize potential health risks.

InChI:InChI=1/C13H11ClO3S/c14-18(15,16)13-8-6-12(7-9-13)17-10-11-4-2-1-3-5-11/h1-9H,10H2

Upstream product

• 111712-04-0 4-phenylmethoxybenzenesulfonic acid sodium salt 
• 5950-16-3 4-(benzyloxy)benzenesulfonic acid 
• 100-39-0 benzyl bromide 
• 825-90-1 sodium p-hydroxybenzenesulfonate 
• 98-67-9 p-hydoroxybenzenesulfonic acid 
• 68-12-2 N,N-dimethyl-formamide 
• 106-41-2 4-bromo-phenol 
• 6793-92-6 p-benzyloxyphenylbromide 
• 95309-80-1 1-benzylsulfanyl-4-benzyloxy-benzene 
• 179246-19-6 bis{4-[(phenylmethyl)oxy]phenyl} disulfide 
• 946-80-5 (benzyloxy)benzene 

Downstream Products

• 591228-77-2 [3-(4-benzyloxy-benzenesulfonylamino)-propyl]-(1-cyclohexylmethyl-piperidin-4-yl)-carbamic acid tert-butyl ester 
• 329041-37-4 4-Benzyloxy-N-[(1R,2S)-2-hydroxy-1-(4-methyl-2,6,7-trioxa-bicyclo[2.2.2]oct-1-yl)-propyl]-benzenesulfonamide 
• 329041-29-4 (1 R ,4 R)-5-(4-Benzyloxy-benzenesulfonyl)-8,8-dimethyl-2-oxa-5-aza-bicyclo[2.2.2]octan-3-one 
• 329041-19-2 [4-benzyloxybenzenesulfonylamino]-acetic acid tert-butyl ester 
• 863483-28-7 N-((1S,2S)-2-amino-1,2-diphenylethyl)-4-(benzyloxy)benzenesulfonamide 
• 911067-22-6 {(1S,2R)-1-Benzyl-3-[(4-benzyloxy-benzenesulfonyl)-isobutyl-amino]-2-hydroxy-propyl}-carbamic acid tert-butyl ester 
• 937802-43-2 C₁₀H₁₃NO₄S 
• 937802-44-3 C₁₃H₁₅NO₄S 
• 937802-45-4 C₁₉H₂₆N₂O₄S 
• 937802-49-8 C₂₁H₂₈N₂O₄S₂ 
• 937802-46-5 C₁₉H₂₇N₃O₄S 
• 937802-50-1 C₂₁H₂₉N₃O₄S₂ 
• 448963-99-3 (1R,5S)-2-(4-Hydroxy-benzenesulfonyl)-6-oxa-2-aza-bicyclo[3.2.1]octan-7-one 
• 448964-10-1 (1R,5S)-2-[4-(4-Chloro-benzyloxy)-benzenesulfonyl]-6-oxa-2-aza-bicyclo[3.2.1]octan-7-one 

Relevant academic research and scientific papers

SMALL MOLECULE DIRECT INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION

This patent document diclsoes novel compounds and methods of preventing or treating diseases or conditions related to Keapl-Nrf2 interaction activity by use of the novel compounds. As direct inhibitors of Keapl-Nrf2 interaction, the compounds disclosed herein are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential dmg candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, Alzheimer's, Parkinson's, and inflammatory bowel disease including ulcerative colitis.

MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of Kirsten rat sarcoma protein (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation, accumulation, and/or overactivation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS

The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist- induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

Fragment-Based Design, Synthesis, and Biological Evaluation of 1-Substituted-indole-2-carboxylic Acids as Selective Mcl-1 Inhibitors

Based on a known selective Mcl-1 inhibitor, 6-chloro-3-(3-(4-chloro-3,5-dimethylphenoxy)propyl)-1H-indole-2-carboxylic acid, we applied a fragment-based approach to obtain new molecules that extended into the p1 pocket of the BH3 groove and then exhibited binding selectivity for the Mcl-1 over the Bcl-2 protein. After we deconstructed the 1H-indole-2-carboxylic acid from the parental molecule, a benzenesulfonyl was substituted at the 1-position to adopt a geometry preferred for accessing the p1 pocket according to the binding mode of the parental molecule identified by X-ray crystallography. A linear relationship between the free energy of ligand binding (ΔG) and the count of non-hydrogen heavy atoms (HAC) was maintained during the molecular growing to occupy the p1 pocket. Finally, we not only obtained compound 12 with a 7.5-fold selectivity to Mcl-1 (Ki = 0.48 μM by fluorescence polarization) over Bcl-2 (Ki = 3.6 μM), but also provided evidence that additional occupation of the p1 pocket is more favorable for Mcl-1 than for Bcl-2 binding, and contributes more to Mcl-1 inhibition than occupation of the p2 pocket. Compound 12 exhibited a selective killing ability on Mcl-1-dependent cancer cells.

COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS

The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease,

NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS

Provided herein are novel benzenesulfonamide compounds having a structure of formula (I) below: as well as to the method for synthesizing same and to the use thereof in pharmaceutical compositions to be used in human or veterinary medicine, as well as to

Fluorescent non-peptidic RGD mimetics with high selectivity for αvβ3 vs αiIbβ3 integrin receptor: Novel probes for in vivo optical imaging

Integrins are heterodimeric transmembrane protein receptors consisting of different α and β subunits. αvβ3 integrins are overexpressed on many tumor cells and tumor-associated angiogenic vessels, whereas αIIbβ3 is a receptor for, e.g., fibrinogen and mediates platelet aggregation. In this study, a near-infrared fluorescent imaging probe has been designed and synthesized by conjugating fluorescent dyes to a non-peptidic, pharmacophore-based ligand, based on a molecular modeling design approach. Affinity values were determined, and in vitro cell binding assays and preliminary in vivo xenograft studies in nude mice were performed to evaluate target binding. Competition assays revealed excellent binding and selectivity to αvβ3 compared to that for αIIbβ3. In vitro, the probe showed high target binding on αvβ3-positive M-21 cells and negligible binding to αvβ3-negative MCF-7 cells. In vivo, the tracer is able to image target expression in U-87 xenografts with a maximum signal-to-noise ratio (SNR) of 2.5:1 at 24 h after injection.

Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: Synthesis and biological evaluation

Aggrecanases, in particular aggrecanase-2 (ADAMTS-5), are considered the principal proteases responsible for aggrecan degradation in osteoarthritis. For this reason, considerable effort has been put on the discovery and development of aggrecanase inhibito

NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS

Benzenesulfonamide compounds having a structure of the following general formula (I) are described. Also described, are methods for synthesizing the compounds, and to the use thereof in pharmaceutical compositions for human or veterinary medicine and in c